Unknown

Dataset Information

0

?-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy.


ABSTRACT: Nuclear activated ?-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring different Wnt/?-catenin pathway mutations in APC/KRAS or ?-catenin/KRAS genes, and both genetic and pharmacological knockdown approaches, we show that oncogenic ?-catenin signaling negatively regulates the expression of NHERF1 (Na+/H+ exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or downregulated in early dysplastic adenomas to exacerbate nuclear ?-catenin activity. Chromatin immunoprecipitation (ChIP) assays demonstrated that ?-catenin represses NHERF1 via TCF4 directly, while the association between TCF1 and the Nherf1 promoter increased upon ?-catenin knockdown. To note, the occurrence of a cytostatic survival response in settings of single ?-catenin-depleted CRC cells was abrogated by combining NHERF1 inhibition via small hairpin RNA (shRNA) or RS5517, a novel PDZ1-domain ligand of NHERF1 that prevented its ectopic nuclear entry. Mechanistically, dual NHERF1/?-catenin targeting promoted an autophagy-to-apoptosis switch consistent with the activation of Caspase-3, the cleavage of PARP and reduced levels of phospho-ERK1/2, Beclin-1, and Rab7 autophagic proteins compared with ?-catenin knockdown alone. Collectively, our data unveil novel ?-catenin/TCF-dependent mechanisms of CRC carcinogenesis, also offering preclinical proof of concept for combining ?-catenin and NHERF1 pharmacological inhibitors as a mechanism-based strategy to augment apoptotic death of CRC cells refractory to current Wnt/?-catenin-targeted therapeutics.

SUBMITTER: Saponaro C 

PROVIDER: S-EPMC6002344 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


Nuclear activated β-catenin plays a causative role in colorectal cancers (CRC) but remains an elusive therapeutic target. Using human CRC cells harboring different Wnt/β-catenin pathway mutations in APC/KRAS or β-catenin/KRAS genes, and both genetic and pharmacological knockdown approaches, we show that oncogenic β-catenin signaling negatively regulates the expression of NHERF1 (Na<sup>+</sup>/H<sup>+</sup> exchanger 3 regulating factor 1), a PDZ-adaptor protein that is usually lost or downregul  ...[more]

Similar Datasets

| S-EPMC5018097 | biostudies-literature
| S-EPMC3612914 | biostudies-literature
| S-EPMC8321723 | biostudies-literature
| S-EPMC5320608 | biostudies-other
| S-EPMC10718136 | biostudies-literature
| S-EPMC9438178 | biostudies-literature
| S-EPMC6996851 | biostudies-literature
| S-EPMC10355916 | biostudies-literature
| S-EPMC8165599 | biostudies-literature
| S-EPMC4669687 | biostudies-literature